News TAE raises $40m to develop new targeted radiotherapy Medtech firm TAE Life Sciences is developing a ground-breaking radiotherapy technology which will be able to treat hard-to-reach cancers with targeted beams.
Views & Analysis Kick-starting innovation in Glioblastoma Can risk-sharing and real-world evidence can provide traction in treating the brain cancer Glioblastoma?
News Tocagen’s brain tumour candidate gets PRIME designation An early-stage drug candidate for hard-to-treat brain tumours has been granted special ‘PRIME’ status by the European Medicines Agency.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face